首页> 外文期刊>Biomedical Chromatography: An International Journal Devoted to Research in Chromatographic Methodologies and Their Applications in the Biosciences >Incurred sample reanalysis: dilemma in its applicability - should it be practiced for all bioanalytical assays involving single (parent or metabolite) or multiple analytes (parent/metabolite or parent with co-administered drugs)?
【24h】

Incurred sample reanalysis: dilemma in its applicability - should it be practiced for all bioanalytical assays involving single (parent or metabolite) or multiple analytes (parent/metabolite or parent with co-administered drugs)?

机译:样品再分析:适用性的困境–是否应针对涉及单个(母体或代谢产物)或多种分析物(母体/代谢物或母体与共同给药药物)的所有生物分析方法进行实践?

获取原文
获取原文并翻译 | 示例
       

摘要

The intent of this note is to provide some perspectives and dilemma in the use of incurred sample reanalysis (ISR) in the real world.ISR has gained a lot of momentum in the last few years such that it is now being considered as an integral part of method validation procedure(s), especially when new assays for novel chemical entities (NCEs) and/or important drugs are being developed and marketed (Silvestro et al., 2010; Jemal et al., 2002, 2010; Zhang ef al., 2009, 2010b; Xu et al., 2009; Fast et al., 2009; Anderson et al., 2009; Myasein ef al., 2009; Wu et al., 2008; Huang et al., 2008; Rocci et al., 2007; Larsson and Han, 2007; Brockman et al., 2007). Recently, in a well-compiled report, discussions on the requirements of ISR for macromolecules, with appropriate statistical control, were eloquently presented (Thway et al., 2010). Interestingly, the same level of scrutiny for ISR seems to wither away as NCEs undergo further clinical development. It may be argued that ISR once established should support the analysis of the chosen NCE in the same matrix with all associated extraction/chromatographic/detection conditions and, hence, repetition of such analyses adds no value commensurate with expended resources. However, in some instances the assay(s) for parent NCE are significantly modified within the same matrix with the involvement of at least one of the following: (1) change in extraction system - liquid-liquid extraction converted to solid-phase extraction or vice versa; (2) altered chromatographic conditions - not merely change in flow rate and/or minor tweaking but change in the analytical column or quantitative change in the composition of mobile phase with changes in detection system; and (3) incorporation of other analytes such as key metabolites or co-administered drugs for quantitation under identical conditions as used before. While one needs to be pragmatic in making calls for the need for repeated ISR, it needs to be judicious and well thought-out, su...
机译:本说明的目的是为在现实世界中使用样本再分析(ISR)提供一些观点和困境.ISR在过去几年中获得了很大的发展势头,因此现在已被视为不可或缺的一部分方法验证程序的使用,特别是当正在开发和销售针对新型化学实体(NCE)和/或重要药物的新测定法时(Silvestro等人,2010; Jemal等人,2002,2010; Zhang等人。 ,2009,2010b; Xu等,2009; Fast等,2009; Anderson等,2009; Myasein等,2009; Wu等,2008; Huang等,2008; Rocci等。 ,2007; Larsson和Han,2007; Brockman等,2007)。最近,在一份精心编写的报告中,雄辩地提出了有关ISR对大分子的要求以及适当的统计控制的讨论(Thway等,2010)。有趣的是,随着NCE进行进一步的临床开发,对ISR进行同样程度的审查似乎正在消失。可能会争辩说,一旦建立了ISR,应在所有相关的提取/色谱/检测条件下支持对同一基质中所选NCE的分析,因此,重复进行此类分析不会增加与消耗的资源相对应的价值。但是,在某些情况下,涉及母体NCE的检测方法在以下至少一种情况下会在同一基质中发生显着变化:(1)萃取系统的变化-液-液萃取转化为固相萃取或反之亦然; (2)改变的色谱条件-不仅改变流速和/或进行细微调整,而且随着检测系统的变化,分析柱的变化或流动相组成的定量变化; (3)掺入其他分析物,例如关键代谢物或共同给药的药物,以便在与以前相同的条件下进行定量。尽管在呼吁重复ISR时需要务实,但它必须明智且经过深思熟虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号